ClinicalTrials.gg
RecruitingNCT07268560AWAREUpdated Mar 23, 2026

Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE

An observational study in Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP), sponsored by Sir Run Run Shaw Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Primary conditionPneumonia, Ventilator-AssociatedRegistry: Healthcare-Associated PneumoniaReclassifiedWhy we changed it
Registry
Healthcare-Associated Pneumonia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pneumonia, Ventilator-Associated
Why
  1. The study's listed conditions name Pneumonia, Ventilator-Associated, a narrower term within Healthcare-Associated Pneumonia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sir Run Run Shaw Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Pneumonia, Ventilator-Associated with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Pneumonia, Ventilator-Associated · China.

Started
2025
with 4 others
Observational
9 of 26
4 open now
Primary completion
2027-07
later than 6 of 10 live
Registered
22nd of 26
by date

Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, this one is one of 5 that started in 2025, is one of 9 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 22nd registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

10 of the 26 studies in Pneumonia, Ventilator-Associated with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pneumonia, Ventilator-Associated with a site in China, or all of them as a file.
02

Study summary

Why This Study is Needed Some bacterial infections have become resistant to common antibiotics, making them very difficult to treat. This is a growing and serious health problem. A new combination drug, Aztreonam-Avibactam (we'll call it ATM-AVI), has been developed to fight these tough bacteria.

This new drug was recently approved for use in Europe (April 2024), the United States (February 2025), and China (June 2025). Because it is so new, there is very little information available, especially in China, on how well it works for real patients outside of initial testing.

This lack of real-world experience means we don't know enough about:

  • How effective it is for typical patients in China.
  • The types of patients and infections it is used for.
  • How it affects a patient's time in the hospital. This study aims to fill these gaps by looking at how ATM-AVI performs in Chinese hospitals, which will help doctors better treat these dangerous infections and improve patient recovery.

What the Study Aims to Find Out

Main Goal:

To see how well ATM-AVI works for adult patients in China with these specific antibiotic-resistant infections.

Other Goals:

To gather more details about:

  • How patients are responding to the treatment at different points (e.g., after 5 days, at the end of treatment, and at a follow-up check).
  • Whether the bacteria causing the infection are cleared.
  • How the treatment affects the patient's hospital stay and use of resources.
  • The number of patients who, unfortunately, pass away during or after treatment.
  • The characteristics of the patients (like age) and their infections.
  • How doctors are using this new drug and if it's used alongside other antibiotics.

How the Study Will Work This is an observational study that will be conducted in about 30 hospitals across China. We plan to include around 100 adult patients who were hospitalized with these tough infections and received the new drug, ATM-AVI, for at least one full day.

The study will run from October 2025 to June 2027. We will look at both past (retrospective) and future (prospective) patients. For past patients, we will review their existing medical records. For future patients, we will ask for their permission (informed consent) before collecting any information.

We will collect information from patient records, such as:

  • Basic patient details and the nature of their infection.
  • How and when the ATM-AVI drug was used.
  • Details about their hospital stay.
  • The results of their lab tests. A doctor will assess and record how each patient is doing at key points: 5 days after starting the drug, at the end of the treatment, and at a follow-up check to see if the infection is cured.
03

Conditions studied

  • Complicated Intra-Abdominal Infections, cIAIs
  • Hospital-acquired Pneumonia (HAP)
  • Ventilator-Associated Pneumonia (VAP)

Browse trials for

04

In context

Pneumonia, Ventilator-Associated Reclassified

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

This study's planned enrollment of 100 is below the median of 170 across 132 observational studies indexed under Pneumonia, Ventilator-Associated.

Browse Pneumonia, Ventilator-Associated studies →

Lead sponsor

Sir Run Run Shaw Hospital is the lead sponsor of 136 studies on the registry; 73 are open to participants now.

Compared within Pneumonia, Ventilator-Associated, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Healthcare-Associated Pneumonia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of hospitalized adult patients with MBL-producing CRE infections treated with ATM-AVI. Investigators will start eligibility screening and recruitment from adult patients who have received ≥24 hours of ATM-AVI.

The index date is defined as the ATM-AVI initiation date, for which the date of first administration is used. The baseline period spans from 14 days before the index date to the index date, or from the date of admission to the index date, whichever is later. The observations will be both retrospective and prospective. Patients will be followed from ATM-AVI use until death, study withdrawal, or hospital discharge, whichever occurs first. For patients discharged before Day 28, a phone follow-up is necessary for assessment of the 28-day all-cause mortality.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age 18 years or older 2. Hospitalized with a diagnosis of confirmed cIAI or HAP/VAP 3. Confirmed infection with MBL-producing CRE 4. Received on label use of ATM-AVI treatment for ≥24 hours 5. will be obtained or waived.

Exclusion criteria

Exclusion Criteria:

  • 1. Confirmed or suspected infection caused by Gram-negative species not expected to respond to ATM-AVI 2. Currently enrolled in an interventional clinical tria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hospitalized adult patients with MBL-producing CRE infections treated with ATM-AVI.

    The study population consists of hospitalized adult patients with MBL-producing CRE infections treated with ATM-AVI. Investigators will start eligibility screening and recruitment from adult patients who have received ≥24 hours of ATM-AVI.

    Drug: Aztreonam-Avibactam

Interventions

  • DrugAztreonam-Avibactam

    Hospitalized adult patients with MBL-producing CRE infections treated with ATM-AVI.

07

What researchers measure

Primary outcomes

  1. The primary efficacy outcome measure is the proportion of patients who had a clinical response of clinical success, failure, and indeterminate, respectively, which will be assessed at the EOT visit.

    The primary descriptive efficacy analysis will be the estimate of the clinical response rate along with nominal 95% CIs using the Clopper-Pearson method.

    Time frame: From enrollment to the end of treatment at 4 weeks

08

Study locations

1 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided — The study will include interim report and a final clinical study report. Upon completion of the study and finalization of the study report, the results of this NI study will be submitted for publication and/or posted in a publicly accessible results database. Publications will adhere to the recommendations of the International Committee of Medical Journal Editors (ICMJE).

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

Of 63 non-industry observational studies under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 19 months is close to that.

Counting every sponsor, half of 63 studies reached it within 20 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 8, 2025
StartActual
Dec 25, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07268560
Collaborators
The First Affiliated Hospital of Nanchang University, Zhejiang Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Dec 25, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Yunsong Yu, PhD
Contact
yvys119@zju.edu.cn
86-13805790432

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion